Fixed Dose Comparison of Escitalopram to an Active Comparator in Severely Depressed Patients

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety and efficacy of escitalopram to an active comparator in severely depressed patients

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Forest Laboratories
• Treatments: Citalopram; Dexetimide

Criteria

Inclusion Criteria:

• Patients must meet DSM-IV criteria for Major Depressive Disorder.

• Patients must have severe depression.

• MADRS greater than or equal to 30

Exclusion Criteria:

• Women who are pregnant, women who will be breastfeeding during the study, and women of childbearing potential who are not practicing a reliable method of birth control.

• Patients who are considered a suicide risk.

• Patients who currently meet DSM-IV criteria for: a principal diagnosis for Axis I disorder other than MDD (comorbid GAD is allowed), bipolar disorder, schizophrenia or any psychotic disorder, obsessive-compulsive disorder, dysthymia.

• Patients with a family history of bipolar disorder, schizophrenia, or any psychotic disorder.

• Patients with history of any psychotic disorder or any psychotic feature.